Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26111479 | 0.88 | — | — | |
| SCHEMBL185337 | 0.88 | — | — | |
| SCHEMBL5026935 | 0.88 | — | — | |
| SCHEMBL22151425 | 0.88 | GABRR1 (0.33) | USP2CYP3A4SMN1; SMN2 | |
| SCHEMBL5067742 | 0.86 | THRB (0.50) | THRBALDH1A1TSHR | |
| SCHEMBL9710237 | 0.85 | GABRR1 (0.32) | — | |
| SCHEMBL1888683 | 0.85 | THRB (0.62) | THRBALDH1A1USP2CYP3A4SMN1; SMN2 | |
| SCHEMBL25949401 | 0.85 | THRB (0.62) | THRBALDH1A1USP2CYP3A4SMN1; SMN2 | |
| SCHEMBL11959164 | 0.83 | USP2 (0.43) | THRBALDH1A1TSHRUSP2CYP3A4 | |
| SCHEMBL13569224 | 0.82 | THRB (0.59) | THRBALDH1A1USP2CYP3A4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1480943-A2 | SYNTHESIS OF 3,5-DIHYDROXY-7-PYRROL-1-YL HEPTANOIC ACIDS | Teva Pharmaceutical Industries Limited (IL) | 2004-12-01 | — | — | EP | claimed |
| WO-2004046105-A2 | SYNTHESIS OF 3,5-DIHYDROXY-7-PYRROL-1-YL HEPTANOIC ACIDS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-06-03 | — | — | WO | claimed |
| US-7932403-B2 | Process for preparing pyrrole derivatives and intermediates | RATIOPHARM GMBH (DE) | 2011-04-26 | — | — | US | disclosed |
| US-20090012312-A1 | Process for Preparing Pyrrole Derivatives and Intermediates | RATIOPHARM GMBH (DE) | 2009-01-08 | — | — | US | disclosed |
| WO-2006066823-A1 | PROCESS FOR PREPARING PYRROLE DERIVATIVES AND INTERMEDIATES | RATIOPHARM GMBH (DE) | 2006-06-29 | — | — | WO | disclosed |
| EP-1671947-A1 | Process for preparing pyrrole derivatives and intermediates | Ratiopharm GmbH (DE) | 2006-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012312-A1 | Process for Preparing Pyrrole Derivatives and Intermediates | DHCR7, DHPS, CYP46A1 | THRB 3371/4885ALDH1A1 651/4885TSHR 4379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.